Logo image of XOMA

XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XOMA - US98419J2069 - Common Stock

26.92 USD
-0.35 (-1.28%)
Last: 1/22/2026, 8:12:13 PM
26.5593 USD
-0.36 (-1.34%)
After Hours: 1/22/2026, 8:12:13 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to XOMA. XOMA was compared to 525 industry peers in the Biotechnology industry. XOMA has a medium profitability rating, but doesn't score so well on its financial health evaluation. XOMA is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • XOMA had positive earnings in the past year.
  • In the past year XOMA had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: XOMA reported negative operating cash flow in multiple years.
XOMA Yearly Net Income VS EBIT VS OCF VS FCFXOMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • XOMA has a better Return On Assets (3.75%) than 89.90% of its industry peers.
  • With an excellent Return On Equity value of 9.14%, XOMA belongs to the best of the industry, outperforming 92.57% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 3.31%, XOMA belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROIC 3.31%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMA Yearly ROA, ROE, ROICXOMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • Looking at the Profit Margin, with a value of 20.96%, XOMA belongs to the top of the industry, outperforming 93.71% of the companies in the same industry.
  • XOMA's Operating Margin of 20.92% is amongst the best of the industry. XOMA outperforms 95.24% of its industry peers.
Industry RankSector Rank
OM 20.92%
PM (TTM) 20.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMA Yearly Profit, Operating, Gross MarginsXOMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

  • XOMA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for XOMA has been increased compared to 1 year ago.
  • Compared to 5 years ago, XOMA has more shares outstanding
  • Compared to 1 year ago, XOMA has a worse debt to assets ratio.
XOMA Yearly Shares OutstandingXOMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMA Yearly Total Debt VS Total AssetsXOMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.47, we must say that XOMA is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of XOMA (-4.47) is comparable to the rest of the industry.
  • XOMA has a Debt/Equity ratio of 0.87. This is a neutral value indicating XOMA is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.87, XOMA is not doing good in the industry: 73.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z -4.47
ROIC/WACC0.37
WACC9.08%
XOMA Yearly LT Debt VS Equity VS FCFXOMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • XOMA has a Current Ratio of 3.91. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
  • XOMA has a Current ratio (3.91) which is in line with its industry peers.
  • XOMA has a Quick Ratio of 3.91. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.91, XOMA perfoms like the industry average, outperforming 48.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 3.91
XOMA Yearly Current Assets VS Current LiabilitesXOMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 135.71% over the past year.
  • Looking at the last year, XOMA shows a very strong growth in Revenue. The Revenue has grown by 103.96%.
  • XOMA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%

3.2 Future

  • Based on estimates for the next years, XOMA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
  • The Revenue is expected to grow by 41.64% on average over the next years. This is a very strong growth
EPS Next Y153.97%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XOMA Yearly Revenue VS EstimatesXOMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
XOMA Yearly EPS VS EstimatesXOMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

  • XOMA is valuated quite expensively with a Price/Earnings ratio of 35.89.
  • XOMA's Price/Earnings ratio is rather cheap when compared to the industry. XOMA is cheaper than 92.19% of the companies in the same industry.
  • XOMA's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.32.
  • The Price/Forward Earnings ratio is 85.62, which means the current valuation is very expensive for XOMA.
  • 88.00% of the companies in the same industry are more expensive than XOMA, based on the Price/Forward Earnings ratio.
  • XOMA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.32.
Industry RankSector Rank
PE 35.89
Fwd PE 85.62
XOMA Price Earnings VS Forward Price EarningsXOMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • XOMA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XOMA is cheaper than 92.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 32.78
XOMA Per share dataXOMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • XOMA's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y46.72%
EPS Next 3Y37.32%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for XOMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (1/22/2026, 8:12:13 PM)

After market: 26.5593 -0.36 (-1.34%)

26.92

-0.35 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-16
Inst Owners67.66%
Inst Owner Change0.08%
Ins Owners1.79%
Ins Owner Change6.97%
Market Cap333.27M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts84
Price Target65.79 (144.39%)
Short Float %4.33%
Short Ratio1.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)-8.73%
PT rev (3m)-7.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100.88%
EPS NY rev (1m)0.31%
EPS NY rev (3m)100.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.35%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-6.15%
Valuation
Industry RankSector Rank
PE 35.89
Fwd PE 85.62
P/S 7.07
P/FCF N/A
P/OCF 60.94
P/B 3.09
P/tB 5.26
EV/EBITDA 32.78
EPS(TTM)0.75
EY2.79%
EPS(NY)0.31
Fwd EY1.17%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.64%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.23
PEG (5Y)N/A
Graham Number12.13
Profitability
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROCE 4.2%
ROIC 3.31%
ROICexc 4.14%
ROICexgc 5.42%
OM 20.92%
PM (TTM) 20.96%
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA 7.77
Cap/Depr 880.03%
Cap/Sales 42.84%
Interest Coverage 0.83
Cash Conversion 45.03%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 3.91
Altman-Z -4.47
F-Score6
WACC9.08%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y153.97%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.59%
EBIT Next 3Y49.29%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A

XOMA ROYALTY CORPORATION / XOMA FAQ

Can you provide the ChartMill fundamental rating for XOMA ROYALTY CORPORATION?

ChartMill assigns a fundamental rating of 5 / 10 to XOMA.


What is the valuation status for XOMA stock?

ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORPORATION (XOMA). This can be considered as Fairly Valued.


How profitable is XOMA ROYALTY CORPORATION (XOMA) stock?

XOMA ROYALTY CORPORATION (XOMA) has a profitability rating of 5 / 10.


How financially healthy is XOMA ROYALTY CORPORATION?

The financial health rating of XOMA ROYALTY CORPORATION (XOMA) is 3 / 10.


What is the earnings growth outlook for XOMA ROYALTY CORPORATION?

The Earnings per Share (EPS) of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 153.97% in the next year.